Factors associated with therapeutic success in HIV-positive individuals in southern Brazil
Open Access
- 25 November 2014
- journal article
- research article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 40 (2) , 192-195
Abstract
Therapeutic success is characterized by undetectable viral load, immune reconstitution confirmed by CD4+ T-cell count and no clinical manifestations of disease. High treatment adherence is a major determinant of therapeutic success that needs prevention of viral replication, allowing immune reconstitution. Adherence to treatment <95% has been associated with both immune and viral failure. The objective of this study was to evaluate factors associated with therapeutic success in adult patients on highly active antiretroviral therapy (HAART) in a specialized centre for HIV-AIDS in southern Brazil, being defined therapeutic success as achieving and maintaining undetectable viral load, stable immune status (CD4+ T lymphocyte count ≥200 cells/mm(3) ) and adherence to HAART ≥ 95%. We conducted a historical cohort study nested in the PC-HIV randomized clinical trial of PC-HIV. We included adults who were on HAART at Pelotas HIV/AIDS Assistance Service between June 2006 and July 2007 and for whom information on treatment adherence, viral load and CD4+ cell count was available. Pregnant women were excluded. We obtained clinical data from medical records and socio-demographic information in an interview. Therapeutic success was defined as achieving and maintaining undetectable viral load, stable immune status (CD4+ T lymphocyte count ≥200 cells/mm(3) ) and adherence to HAART ≥95%. We included 136 patients (60% male) in the cohort study. Mean age was 40 ± 10 years, and median treatment duration was 59 months (IQR 25-93). Family income varied from 0 to 8 times the minimum wage (IQR 1·0-2·3). Therapeutic success was achieved by 90% (122 patients), and it was associated with previously undetectable viral load (PR = 1·30; 95% CI = 1·13-1·49) and treatment adherence prior to study entry (PR = 1·34; 95% CI = 1·07-1·69), independently of sex, age and previous immune status. When undetectable viral load, CD4+ cell count ≥200 cells/mm(3) and treatment adherence above 95% are included in the definition of therapeutic success, the rate was elevated (90%) and the factors associated were previous history of adherence to HAART and previous undetectable viral load.Keywords
Funding Information
- University of California
- US National Institutes of Health
- Fogarty International Center-International Clinical, Operational and Health Services Research Training Award (D43TW005799)
This publication has 17 references indexed in Scilit:
- Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2012
- Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South AfricaPLOS ONE, 2011
- Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort studyBMC Public Health, 2011
- Predictors of Virologic Failure in HIV/AIDS Patients Treated with Highly Active Antiretroviral Therapy in Brasilia, Brazil during 2002–2008Drug Target Insights, 2011
- Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007PLOS ONE, 2009
- The Risk of Virologic Failure Decreases with Duration of HIV Suppression, at Greater than 50% Adherence to Antiretroviral TherapyPLOS ONE, 2009
- CD4+ Response and Subsequent Risk of Death Among Patients on Antiretroviral Therapy in Lusaka, ZambiaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapyAIDS, 2007
- An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adultsAIDS, 2006
- CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/μLHIV Medicine, 2006